Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273020 | 0.92 | — | — | |
| SCHEMBL29178251 | 0.92 | TDP1 (0.38) | HSD17B10TDP1ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL3831383 | 0.89 | TDP1 (0.36) | HSD17B10HTTAPOBEC3AAPOBEC3GTDP1 | |
| Bromide SCHEMBL16765046 | 0.89 | TDP1 (0.36) | HSD17B10TDP1ALDH1A1CYP1A2 | |
| Formic Acid SCHEMBL29763161 | 0.84 | CYP1A2 (0.39) | HSD17B10TDP1ALDH1A1CYP1A2 | |
| SCHEMBL20055717 | 0.80 | HSD17B10 (0.42) | HSD17B10 | |
| SCHEMBL8729 | 0.80 | — | — | |
| SCHEMBL3950444 | 0.80 | — | — | |
| SCHEMBL22048427 | 0.79 | — | — | |
| SCHEMBL21246163 | 0.77 | HTT (0.35) | HTTAPOBEC3AAPOBEC3GLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493545-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-01-22 | — | — | EP | claimed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | claimed |
| WO-2023177563-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-21 | — | — | WO | claimed |
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | claimed |
| CN-114929345-A | Substituted pyrazole compounds as TOLL receptor inhibitors | 百时美施贵宝公司 | 2022-08-19 | — | — | CN | claimed |
| CN-111511730-A | Amide substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | claimed |
| CN-111491918-A | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | claimed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | claimed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | claimed |
| JP-2006519232-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| EP-4493545-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023177563-A2 | FUSED PYRAZOLE AMIDE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7485633-B2 | RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007086080-A2 | NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | HSD17B10 4676/4885HTT 4823/4885APOBEC3A 1733/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | HSD17B10 323/4885HTT 204/4885APOBEC3A 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.